Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without